Maternal immune activation and estrogen receptor modulation induce sex-specific dopamine-related behavioural and molecular alterations in adult rat offspring

• Published in: Brain, behavior, and immunity behavior, and immunity, 2024-05, Vol.118, p.236-251
• Main Authors: Debs, Sophie R., Conn, Illya, Navaneethan, Brendan, Penklis, Andriane G., Meyer, Urs, Killcross, Simon, Weickert, Cynthia Shannon, Purves-Tyson, Tertia D.
• Format: Article
• Language: English
• Subjects: Dopamine; Estrogen; Maternal immune activation (MIA); Neurodevelopment; Raloxifene; Schizophrenia; Selective estrogen receptor modulator (SERM); Sex steroids; Substantia nigra
• ISSN: 0889-1591; 1090-2139
• DOI: 10.1016/j.bbi.2024.02.034

•Chronic raloxifene leads to sex-specific behavioural and molecular changes in MIA offspring.•Raloxifene reduces amphetamine-induced hyperlocomotion and improves prepulse inhibition in male MIA offspring.•MIA and raloxifene alter dopamine-related gene expression in a sex-specific manner in the substantia nigra of adult rats.•The therapeutic effects of raloxifene may be expected to differ between women and men with schizophrenia. Dopamine dysregulation contributes to psychosis and cognitive deficits in schizophrenia that can be modelled in rodents by inducing maternal immune activation (MIA). The selective estrogen receptor (ER) modulator, raloxifene, can improve psychosis and cognition in men and women with schizophrenia. However, few studies have examined how raloxifene may exert its therapeutic effects in mammalian brain in both sexes during young adulthood (age relevant to most prevalent age at diagnosis). Here, we tested the extent to which raloxifene alters dopamine-related behaviours and brain transcripts in young adult rats, both control and MIA-exposed females and males. We found that raloxifene increased amphetamine (AMPH)-induced locomotor activity in female controls, and in contrast, raloxifene reduced AMPH-induced locomotor activity in male MIA offspring. We did not detect overt prepulse inhibition (PPI) deficits in female or male MIA offspring, yet raloxifene enhanced PPI in male MIA offspring. Whereas, raloxifene ameliorated increased startle responsivity in female MIA offspring. In the substantia nigra (SN), we found reduced Drd2s mRNA in raloxifene-treated female offspring with or without MIA, and increased Comt mRNA in placebo-treated male MIA offspring relative to placebo-treated controls. These data demonstrate an underlying dopamine dysregulation in MIA animals that can become more apparent with raloxifene treatment, and may involve selective alterations in dopamine receptor levels and dopamine breakdown processes in the SN. Our findings support sex-specific, differential behavioural responses to ER modulation in MIA compared to control offspring, with beneficial effects of raloxifene treatment on dopamine-related behaviours relevant to schizophrenia found in male MIA offspring only.